Status:
UNKNOWN
Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
Lead Sponsor:
University of Sao Paulo
Conditions:
Carcinoma, Basal Cell
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.
Detailed Description
This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the com...
Eligibility Criteria
Inclusion
- Patients whose injuries were confirmed by anatomical and pathological study (periocular superficial basal cell carcinoma).
- Patients with clinical counter indication for reconstructive surgery (high surgical risk).
- Patients who have refused a restorative surgery. (aesthetic reasons)
- Patients who have signed the free and informed consent.
Exclusion
- Patients who have a hypersensitivity reaction to the formula components.
- Children under 12 years of age.
- Pregnant and breastfeeding women.
- Patients whose injury was not confirmed by anatomical and pathological study.
- Individuals with previous autoimmune or inflammatory disease.
- Patients who have refused to sign the free and informed term of consent.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00803907
Start Date
December 1 2008
End Date
February 1 2013
Last Update
June 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Sao Paulo
São Paulo, São Paulo, Brazil